DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Biological: Upadacitinib
Biological: Dupilumab
Drug: Placebo to upadacitinib
Drug: Placebo to dupilumab

First Posted Date: 2018-11-13

Last Posted Date: 2024-03-15

Lead Sponsor: AbbVie

Target Recruit Count: 673

Registration Number: NCT03738397

Locations: 🇺🇸
Northwestern University Feinberg School of Medicine /ID# 208680, Chicago, Illinois, United States
🇺🇸
Medical Dermatology Associates of Chicago /ID# 210265, Chicago, Illinois, United States
🇺🇸
Miami Dermatology and Laser Institute /ID# 212938, Miami, Florida, United States

and more 156 locations

The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: Cariprazine
Drug: Antidepressant Therapy (ADT)

First Posted Date: 2018-11-13

Last Posted Date: 2022-09-21

Lead Sponsor: AbbVie

Target Recruit Count: 752

Registration Number: NCT03739203

Locations: 🇺🇸
Global Clinical Trials /ID# 235059, Costa Mesa, California, United States
🇺🇸
Institute for Advanced Medical Research /ID# 234992, Atlanta, Georgia, United States
🇺🇸
International Research Associates, LLC /ID# 237410, Miami, Florida, United States

and more 109 locations

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

Phase 2

Completed

Conditions: Multiple Sclerosis (MS)

Interventions: Drug: elezanumab
Drug: placebo

First Posted Date: 2018-11-13

Last Posted Date: 2023-12-22

Lead Sponsor: AbbVie

Target Recruit Count: 208

Registration Number: NCT03737851

Locations: 🇺🇸
Duplicate_Parexel International /ID# 204273, Baltimore, Maryland, United States
🇺🇸
Sutter East Bay Medical Foundation-Jordon Research and Education Dev. Inst. /ID# 204249, Berkeley, California, United States
🇺🇸
UC Irvine Health /ID# 205728, Irvine, California, United States

and more 46 locations

A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis

Phase 3

Completed

Conditions: Giant Cell Arteritis (GCA)

Interventions: Drug: Corticosteroid (CS)
Drug: Upadacitinib
Other: Placebo

First Posted Date: 2018-10-30

Last Posted Date: 2025-03-27

Lead Sponsor: AbbVie

Target Recruit Count: 438

Registration Number: NCT03725202

Locations: 🇺🇸
Omega Research Group /ID# 201903, Orlando, Florida, United States
🇧🇪
Universitair Ziekenhuis Leuven /ID# 202779, Leuven, Vlaams-Brabant, Belgium
🇨🇦
Duplicate_University of Alberta Hospital - Division of Hematology /ID# 208629, Edmonton, Alberta, Canada

and more 169 locations

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis

Phase 1

Active, not recruiting

Conditions: Juvenile Idiopathic Arthritis (JIA)

Interventions: Drug: Upadacitinib

First Posted Date: 2018-10-30

Last Posted Date: 2024-06-20

Lead Sponsor: AbbVie

Target Recruit Count: 122

Registration Number: NCT03725007

Locations: 🇺🇸
Cincinnati Childrens Hospital Medical Center /ID# 209697, Cincinnati, Ohio, United States
🇵🇷
Centro de Reumatologia Pediatrico de Puerto Rico /Id# 204406, Bayamon, Puerto Rico
🇵🇷
Mindful Medical Research /ID# 204488, San Juan, Puerto Rico

and more 32 locations

An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)

Phase 2

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: Tilavonemab

First Posted Date: 2018-10-19

Last Posted Date: 2022-09-22

Lead Sponsor: AbbVie

Target Recruit Count: 364

Registration Number: NCT03712787

Locations: 🇦🇺
Griffith University /ID# 204905, Southport, Queensland, Australia
🇪🇸
Hospital Clinic de Barcelona /ID# 204519, Barcelona, Spain
🇸🇪
Karolinska University Hospital Huddinge /ID# 203900, Stockholm, Stockholms Lan, Sweden

and more 54 locations

A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

Phase 2

Completed

Conditions: Dermatitis

Interventions: Biological: Risankizumab
Biological: Placebo

First Posted Date: 2018-10-15

Last Posted Date: 2021-11-18

Lead Sponsor: AbbVie

Target Recruit Count: 172

Registration Number: NCT03706040

Locations: 🇨🇦
Beacon Dermatology Inc /ID# 213003, Calgary, Alberta, Canada
🇦🇺
Fremantle Dermatology /ID# 204784, Fremantle, Western Australia, Australia
🇺🇸
Center for Dermatology Clinical Research /ID# 204950, Fremont, California, United States

and more 62 locations

A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

Phase 2

Completed

Conditions: Ulcerative Colitis (UC)

Interventions: Drug: Ravagalimab 600 mg
Drug: Ravagalimab 300 mg

First Posted Date: 2018-10-04

Last Posted Date: 2023-03-15

Lead Sponsor: AbbVie

Target Recruit Count: 42

Registration Number: NCT03695185

Locations: 🇺🇸
Banner University Medical Cent /ID# 208392, Tucson, Arizona, United States
🇺🇸
Meridian Investigator Network /ID# 218568, Lakewood, California, United States
🇺🇸
The University of Chicago DCAM /ID# 207086, Chicago, Illinois, United States

and more 31 locations

A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)

Phase 3

Completed

Conditions: Central Precocious Puberty (CPP)

Interventions: Drug: Leuprolide Acetate (LA)

First Posted Date: 2018-10-04

Last Posted Date: 2024-05-29

Lead Sponsor: AbbVie

Target Recruit Count: 45

Registration Number: NCT03695237

Locations: 🇺🇸
Rady Children's Hospital San Diego /ID# 202491, San Diego, California, United States
🇺🇸
Van Meter Pediatric Endocrinology /ID# 201688, Atlanta, Georgia, United States
🇺🇸
Rocky Mountain Diabetes and Osteoporosis Center /ID# 209878, Idaho Falls, Idaho, United States

and more 15 locations

A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis (RA)

Interventions: Drug: Elsubrutinib
Drug: Placebo for elsubrutinib
Drug: Placebo for upadacitinib
Drug: Upadacitinib

First Posted Date: 2018-09-25

Last Posted Date: 2021-05-03

Lead Sponsor: AbbVie

Target Recruit Count: 242

Registration Number: NCT03682705

Locations: 🇺🇸
Tekton Research, Inc. /ID# 167475, Austin, Texas, United States
🇺🇸
Institute of Arthritis Researc /ID# 170694, Idaho Falls, Idaho, United States
🇺🇸
DM Clinical Research /ID# 167444, Tomball, Texas, United States

and more 112 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy